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Available online 15 July 2016Cariprazine, a dopamine D3/D2 receptor partial agonist with preference for D3 receptors, has
demonstrated efﬁcacy in randomized controlled trials in schizophrenia. This multinational, randomized, dou-
ble-blind, placebo-controlled, parallel-group study evaluated the efﬁcacy, safety, and tolerability of cariprazine
for relapse prevention in adults with schizophrenia; total study duration was up to 97 weeks. Schizophrenia
symptoms were treated/stabilized with cariprazine 3–9 mg/d during 20-week open-label treatment consisting
of an 8-week, ﬂexible-dose run-in phase and a 12-week ﬁxed-dose stabilization phase. Stable patients who com-
pleted open-label treatment could be randomized to continued cariprazine (3, 6, or 9 mg/d) or placebo
for double-blind treatment (up to 72 weeks). The primary efﬁcacy parameter was time to relapse (worsening
of symptom scores, psychiatric hospitalization, aggressive/violent behavior, or suicidal risk); clinical measures
were implemented to ensure safety in case of impending relapse. A total of 264/765 patients completed open-
label treatment; 200 eligible patients were randomized to double-blind placebo (n = 99) or cariprazine (n =
101). Time to relapse was signiﬁcantly longer in cariprazine- versus placebo-treated patients (P= .0010, log-
rank test). Relapse occurred in 24.8% of cariprazine- and 47.5% of placebo-treated patients (hazard ratio [95%
CI]= 0.45 [0.28, 0.73]). Akathisia (19.2%), insomnia (14.4%), and headache (12.0%) were reported in ≥10% of pa-
tients during open-label treatment; there were no cariprazine adverse events ≥10% during double-blind treat-
ment. Long-term cariprazine treatment was signiﬁcantly more effective than placebo for relapse prevention in
patients with schizophrenia. The long-term safety proﬁle in this study was consistent with the safety proﬁle ob-
served in previous cariprazine clinical trials. ClincalTrials.gov identiﬁer: NCT01412060.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Oral antipsychotics1. Introduction
Schizophrenia is a serious neuropsychiatric syndrome that often has
a severe and chronic course (Emsley et al., 2013); it substantially con-
tributes to the burden of disease attributable tomental health disorders
globally (Whiteford et al., 2013). Relapses in schizophrenia are com-
mon, with each subsequent event contributing to clinical deterioration
including worsening of symptoms, cognitive impairment, reduced so-
cial and vocational functioning, and diminished quality of life
(Fleischhacker et al., 2014; Lehman et al., 2004; Olivares et al., 2013;Financial Center, Jersey City, NJ
am).
aithersburg, MD, USA.
. This is an open access article underTaylor et al., 2005). Although long-term antipsychotic treatment may
substantially reduce relapse risk in the stable phase of schizophrenia
(Kane, 2007), partial or total nonadherence to medication is a ubiqui-
tous clinical problem (Leucht and Heres, 2006; Morken et al., 2008).
Prevention of relapse is an integral component of comprehensive
schizophrenia management.
Cariprazine is a dopamineD3 andD2 receptor partial agonist antipsy-
chotic with preferential binding to D3 receptors (Kiss et al., 2010). Un-
like other new generation antipsychotics, which display high
occupancy at D2 receptors but low or negligible occupancy at D3 recep-
tors (Graff-Guerrero et al., 2009; Gyertyán et al., 2011; Mizrahi et al.,
2011), cariprazine shows high and balanced occupancy of D3 and D2 re-
ceptors at doses effective for the treatment of psychosis (Gyertyán et al.,
2011; Kiss et al., 2010). This pharmacological proﬁle may provide bene-
ﬁts in treating cognitive impairment, negative symptoms, and moodthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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al., 2008; Laszy et al., 2005; Schwartz et al., 2000). Cariprazine also has a
unique pharmacokinetic proﬁle, with 2 major active metabolites,
desmethyl cariprazine and didesmethyl cariprazine. The effective half-
life for the total active moieties, which takes into account cariprazine
and the 2 major active metabolites, is approximately 1 week
(Nakamura et al., 2016). This long half-life may confer some continued
effect after drug discontinuation, perhaps providing protection against
rapid onset of relapse in cases of nonadherence. The efﬁcacy and safety
of cariprazine in patients with schizophrenia have been supported in 3
positive randomized, placebo-controlled, phase II/III clinical studies
(Durgamet al., 2014, 2015; Kane et al., 2015). The current studywas de-
signed to assess the efﬁcacy, safety, and tolerability of long-term treat-
ment with cariprazine for preventing symptomatic relapse in patients
with schizophrenia (ClinicalTrials.gov. NCT01412060).
2. Patients and methods
This study was conducted from 2011 to 2014 in 72 centers (United
States, India, Romania, Slovakia, and Ukraine) in accordance with the
Declaration of Helsinki and ICH Guidance. Sites obtained institutional
review board (US centers) or ethics committee/government agency
(non-US centers) approval before the study. All participants provided
written informed consent.
To identify early signs of relapse and ensure patient safety in the
event of relapse, patients were required to have up to 2 consented care-
givers who also assisted with hospitalization discharges, medication
compliance, and study visits. Unscheduled study visits could be ar-
ranged in cases of potential relapse.
2.1. Study design
This study consisted of 5 phases (screening, open-label run-in, open-
label stabilization, double-blind treatment, safety follow-up) with a
total duration up to 97 weeks; dosing was ﬂexible (cariprazine 3–
9 mg/d) or ﬁxed (cariprazine 3, 6, or 9 mg/d) depending on the study
phase (Fig. 1). Patients were required to complete the prior study
phase and meet all of the following eligibility criteria to progress from
open-label run-in to open-label stabilization (end of week 8) and from
open-label stabilization to double-blind treatment (end of week 20):
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) total
score ≤ 60; at least 20% decrease in PANSS total score from baseline;
Clinical Global Impressions-Severity of Illness (CGI-S) (Guy, 1976b)
score ≤ 4; score ≤ 4 on each of 7 PANSS items (delusions, conceptualFig. 1. Study design. Patientswere assessed for eligibility to enter the open-label run-inphase du
meet eligibility criteria at the end of the run-in phase (week 8) and at the end of the stabilization
eligibility criteria after eachphasewere randomized (1:1) to double-blind treatment. Cariprazin
response and no signiﬁcant tolerability issues (investigator judged), dosage increases were allo
needed. Flexible-dose cariprazine 3–9 mg/d was continued through week 6 of the run-in phas
weeks 7 and 8. During the open-label stabilization phase, cariprazine was continued at the sa
were allowed for signiﬁcant tolerability issues. During double-blind treatment, cariprazine w
were allowed. During the safety follow-up, patients continued as outpatients and received treadisorganization, hallucinatory behavior, suspiciousness/persecution,
hostility, uncooperativeness, and poor impulse control); and no signiﬁ-
cant tolerability issues (investigator judged). Patients who did not meet
eligibility criteria at the endof each open-label phasewere discontinued
from the study and seen for a ﬁnal/early termination visit.
Patients were hospitalized during screening and for the ﬁrst 2weeks
of the run-in phase; they were then either discharged and followed-up
as outpatients, or hospitalized for 2 additional weeks (investigator dis-
cretion). Patients unable to be discharged after 4 weeks were
discontinued due to insufﬁcient therapeutic response or unavailability
of a caregiver.
Patientswere randomized (1:1) to ﬁxed-dose cariprazine or placebo
for double-blind treatment of variable duration (26–72 weeks or until
early termination including a relapse event) (Fig. 1). Per protocol, dou-
ble-blind treatment for all active patients was stopped when the last
randomized patient completed 26 weeks of treatment regardless of
the number of relapse events. Investigators and patients were blinded
to the double-blind treatment assignment through an interactive web
response system; identically appearing treatments were used. Breaking
the randomization code disqualiﬁed the patient from further
participation.
2.2. Patients
To be included,male or female inpatients (18–60 years of age, inclu-
sive)were required to have a currentDiagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2000)
diagnosis of schizophrenia (minimum 1 year) and a current psychotic
episode b 4 weeks' duration. Patients additionally had a PANSS total
score ≥ 70 and ≤120, and a score ≥ 4 (moderately severe) on at least 2
PANSS positive symptoms (delusions, hallucinatory behavior, concep-
tual disorganization, suspiciousness/persecution). Patients in their ﬁrst
psychotic episode were excluded; various psychiatric conditions other
than schizophrenia or concurrent medical conditions that could inter-
ferewith study conduct, confound interpretation of results, or endanger
patient well-being were also exclusionary. Additional exclusion criteria
are presented in Table S1.
2.3. Efﬁcacy assessments
The primary efﬁcacy parameter was time to ﬁrst relapse during dou-
ble-blind treatment (number of days from randomization to the relapse
date); patients who did not meet relapse criteria were considered cen-
sored at the time of completion or discontinuation from the study.ring a no-drug screening period. Toprogress through open-label treatment, patients had to
phase (week 20) (see Section 2.1). Patientswho completed open-label treatment andmet
ewas initiated at 1.5mg/d and increased to 3.0mg/d onday 2; for patientswith inadequate
wed on day 6 (6.0 mg/d [interim increase to 4.5 mg/d on day 4]) and day 10 (9.0 mg/d) if
e; ﬁxed-dose cariprazine 3, 6, or 9 mg/d (no adjustments allowed) was administered for
me ﬁxed dose as in the last 2 weeks of the run-in phase; dose decreases to 3 or 6 mg/d
as administered at the same ﬁxed dose as in the stabilization phase but no adjustments
tment as usual at the discretion of the investigator; patients did not receive study drug.
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clinical measures (Table 1); patients meeting any relapse criterion
were discontinued from the study. Therewas no prespeciﬁed secondary
efﬁcacy parameter. Additional efﬁcacy parameters and safety assess-
ments are presented in Table 1.2.4. Statistical analyses
Safety parameterswere analyzed descriptively for the safety popula-
tions (open-label: eligible patients who took ≥1 dose of open-label
cariprazine; double-blind: randomized patients who took ≥1 dose of
double-blind study drug). Efﬁcacy outcomes were analyzed in the in-
tent-to-treat (ITT) populations (open-label: open-label safety popula-
tion patients with ≥1 postbaseline PANSS assessment during either
open-label phase; double-blind: double-blind safety population pa-
tients with ≥1 PANSS or CGI-S assessment during double-blind treat-
ment). The instruments used to assess safety and efﬁcacy outcomes
were administered by qualiﬁed raters who met training requirements
and qualiﬁcation criteria set forth by the rater training vendor (Bracket,
a division of United Biosource Corporation). The open-label baseline
was the last measurement before beginning open-label treatment; the
double-blind baseline was the last measurement during open-label
treatment. The open-label baseline was used for analyses of safety
parameters.
The primary efﬁcacy analysis compared time to relapse between
placebo and cariprazine using the log-rank test. Hazard ratio (HR)
estimates and 95% conﬁdence interval (CI) were based on the Cox
proportional hazards model with treatment group as an explanatory
variable. The cumulative distribution function of time to relapsewas es-
timated by Kaplan–Meier curves. Additional efﬁcacy parameters were
analyzed descriptively in the open-label and double-blind ITT
populations; missing values were imputed separately for each study
phase using a last observation carried forward (LOCF) approach.
It was estimated that ~80 total relapse events needed to be observed
during the double-blind phase, including both cariprazine and placebo
groups, to have 90% power to detect a statistically signiﬁcant difference
between cariprazine and placebo with a hazard ratio of 0.48 at an over-
all 5% level of signiﬁcance and that 180 randomized patients (~90 per
treatment group) in double-blind treatment would have provided the
required total number of relapse events.Table 1
Relapse criteria, additional efﬁcacy parameters, and safety assessments.
Relapse criteria (meeting any 1 of the relapse criteria was considered a relapse)
Rating scale criteria (conﬁrmed at a repeat visit within 7 days at the investigator's discreti
Increase ≥30% in PANSS total score for patients who scored ≥50 at randomization or a
Score N 4 on any of the 7 PANSS items assessed at randomization (delusions, conceptu
hostility, uncooperativeness, poor impulse control)
CGI-S score increase ≥ 2 points from randomization
Clinical relapse criteria (investigator judged):
Psychiatric hospitalization due to worsening of schizophrenia
Deliberate self-injury or aggressive/violent behavior
Clinically signiﬁcant suicidal/homicidal ideation
Additional efﬁcacy parameters: mean change from baseline
PANSS, CGI-S, CGI-I (all open-label visits, all double-blind study visits through week 3
NSA-16, PSP (open-label weeks 0, 8, and 20, and double-blind weeks 32, 46, 58, 70, 82
Safety assessments
Spontaneously reported adverse events
Vital signs, clinical laboratory tests, electrocardiograms
Physical and ophthalmologic examinations
C-SSRS (to assess suicidal ideation and behavior)
AIMS, BARS, and SAS (to assess EPS)
AIMS, Abnormal Involuntary Movement Scale (Guy, 1976a); BARS, Barnes Akathisia Rating Sc
Clinical Global Impressions-Severity; C-SSRS, Columbia-Suicide Severity Rating Scale (Posne
(Axelrod et al., 1993); PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Soc
Angus, 1970).3. Results
3.1. Patient disposition
Patient disposition and reasons for study withdrawal are presented
in Fig. 2.During open-label treatment, themost common reason for dis-
continuation was withdrawal of consent (~20%). When queried to en-
sure that AEs were not the reason for discontinuation, some patients
indicated that they were unable to continue due to the length of the
study (up to 92-weeks) and the time commitment involved. During
double-blind treatment, per protocol discontinuation (i.e., once the
last randomized patient completed 26weeks of double-blind treatment,
double-blind treatmentwas stopped for all active patients per protocol)
was themost common reason for discontinuation (cariprazine=20.8%;
placebo = 9.1%) other than relapse. Most demographic characteristics
were similar among groups; a statistically signiﬁcant difference be-
tween groups was observed in the distribution of males and females
in the double-blind phase (Table 2).3.2. Efﬁcacy analyses
Time to relapsewas signiﬁcantly longer for cariprazine versus placebo
(Fig. 3). Overall, relapse occurred in 47.5% (47/99) of placebo- and 24.8%
(25/101) of cariprazine-treated patients. The hazard of relapse for
cariprazine-treated patientswas estimated to be less than half that of pla-
cebo-treated patients (HR [95% CI] = 0.45 [0.28, 0.73]). The most com-
monly met relapse criteria in the placebo- and cariprazine-treatment
groups, respectively, were increase in PANSS score (43.4% and 20.8%), in-
crease in CGI-S (28.3% and 4.0%), and score ≥ 4 on any of the assessed
PANSS items (25.3% and 10.9%). The psychiatric hospitalization criterion
wasmet by 9.1% and8.9% of placebo- and cariprazine-treated patients, re-
spectively. Relapse rates atweeks 2, 4, and6, respectively,were similar for
placebo-treated patients (2 [2%], 3 [3%], 11 [12%]) and cariprazine-treated
patients (2 [2%], 7 [7%], 8 [8.0%]); relapse rates began to diverge atweek 8
(placebo = 18 [19%]; cariprazine = 11 [11%]).
At the end of open-label treatment, mean improvements in PANSS
total and subscale scores, CGI-S, NSA-16 total, and PSP scores were ob-
served; at the end of double-blind treatment, scores on these scales
worsened to a greater extent for placebo-treated patients than for
cariprazine-treated patients (Table 3).on):
≥10-point increase for patients who scored b50 at randomization
al disorganization, hallucinatory behavior, suspiciousness/persecution,
2, and every other visit thereafter)
, and 92)
ale (Barnes, 1989); CGI-I, Clinical Global Impressions-Improvement (Guy, 1976b); CGI-S,
r et al., 2011); EPS, extrapyramidal symptoms; NSA-16, Negative Symptom Assessment
ial Performance Scale (Morosini et al., 2000); SAS, Simpson-Angus Scale (Simpson and
Fig. 2. Patient disposition. aOpen-label phase included an 8-week run-in phase and a 12-week stabilization phase; bincludes patients that did not meet criteria to continue into open-label
stabilization phase; c55 patients completed the open-label phase and met the randomization criteria but were not randomized because the number of patients exceeded a prespeciﬁed
country-speciﬁc (India) randomization cap; dthe number of patients in the double-blind safety and ITT populations were identical (cariprazine = 101; placebo = 99); esigniﬁcantly
more cariprazine- (57.4%) than placebo-treated patients (36.4%) prematurely discontinued for reasons other than relapse (P= .0031).
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3.3.1. Extent of exposure
Mean (SD) duration of cariprazine exposure was 75.7 (54.2) days
and 257 (184.0) days in the open-label and double-blind safety popula-
tions, respectively; mean duration of placebo exposure was 205.9
(176.7) days. At randomization, 14 patients were taking cariprazineTable 2
Patient characteristics (safety population).
Open-label p
Cariprazine
3–9 mg/d
n= 765
Demographic characteristics
Age, mean (SD), years 38.4 (10.4)
Men, n (%) 544 (71.1)
Women, n (%) 221 (28.9)
Race, n (%)
White 299 (39.1)
Black/African-American 313 (40.9)
Asian 149 (19.5)
Other 4 (0.5)
Weight, mean (SD), kg 78.1 (20.1)
Body mass index, mean (SD), kg/m2 26.5 (5.6)
Schizophrenia history
Paranoid type, n (%) 712 (93.1)
Duration of illness, mean (SD), years 12.9 (10.2)
Duration of current episode, mean (SD), weeks 2.2 (0.9)
Number of prior hospitalizations, mean (SD) 6.4 (8.8)
History of violent behavior, n (%) 70 (9.2)
History of suicide attempt, n (%) 123 (16.1)
a A statistically signiﬁcant difference between treatment groups was observed for the distrib
Haenszel test; P=.0361).3 mg/d, 37 patients were taking 6 mg/d, and 50 patients were taking
9 mg/d.
3.3.2. Adverse events
An overall summary of AEs is presented in Table 4. Treatment-emer-
gent AEs (TEAEs) that occurred in ≥10% of patients during open-label
treatment were akathisia, headache, and insomnia; during double-hase Double-blind phase
Placebo
n= 99
Cariprazine
3–9 mg/d
n= 101
37.7 (10.1) 39.2 (10.9)
70 (70.7)a 62 (61.4)a
29 (29.3) 39 (38.6)
38 (38.4) 45 (44.6)
30 (30.3) 31 (30.7)
30 (30.3) 25 (24.8)
1 (1.0) 0
74.9 (18.5) 75.8 (20.3)
26.2 (5.5) 26.4 (5.9)
94 (94.9) 97 (96.0)
10.5 (9.5) 11.9 (10.4)
2.2 (1.0) 2.1 (0.9)
3.8 (4.4) 5.3 (6.1)
7 (7.1) 10 (9.9)
14 (14.1) 12 (11.9)
ution of males and females in the double-blind safety population (Cochran-Mantel-
Fig. 3. Cumulative rate of relapse (double-blind ITT population). The 25th percentile for
time to relapse was 92 days in the placebo group and 224 days in the cariprazine group;
the 50th percentile (median) was 296 days for the placebo group and it could not be
calculated for the cariprazine group because of the low number of relapse events.
Between-group separation of the curves did not occur until around day 50.
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≥5% of cariprazine patients and at an incidence at least twice that of pla-
cebo. The incidence of akathisia, the most common open-label TEAE,
was higher during the run-in phase (18.6%) than in the stabilization
phase (6%) or double-blind treatment (placebo = 3%; cariprazine =
5%). Greater than 98% of akathisia was considered mild or moderate.
The overall incidence of EPS TEAEs (excluding akathisia and restless-
ness) was 19.7% during open-label treatment, and 3% and 15.8% for pla-
cebo- and cariprazine-treated patients, respectively, during double-
blind treatment.
Worsening of schizophrenia was the only AE leading to the discon-
tinuation of ≥2% of patients during the open-label (3.0%) and double-
blind (placebo, 9.1%; cariprazine, 5.9%) phases. During open-label treat-
ment, akathisia and other EPS AEs (excluding akathisia or restlessness)
each led to discontinuation in approximately 1% of patients; no EPS-re-
lated AEs led to discontinuation during double-blind treatment. TEAEs
were considered related to treatment in 60.5% and 44.6% of
cariprazine-treated patients during open-label and double-blind treat-
ment, respectively, and in 32.3% of placebo-treated patients during dou-
ble-blind treatment. Most double-blind TEAEs were considered mild or
moderate in severity (placebo = 95.4%; cariprazine = 95.7%).
The only serious AE (SAE) reported in ≥2% of patients during open-
label treatment was worsening of schizophrenia (2.9%); during dou-
ble-blind treatment, SAEs reported in ≥2% of patients in either the pla-
cebo- or cariprazine-treatment groups, respectively, were worsening
of schizophrenia (7.1% and 6.9%), and psychotic disorder (2.0% and
2.0%). All other SAEs reported during the study were reported in ≤1%
of patients.
A summary of laboratory values and signiﬁcant treatment-emergent
changes in lipids and glucose are presented in Tables S2 and S3. MeanTable 3
Additional efﬁcacy outcomes (ITT populations).
Open-label phase
Cariprazine 3–9 mg/d
n= 751
Baseline (SD) Mean change (SD)
PANSS scores
Total 91.3 (10.1) −22.8 (19.8)
Positive subscale 24.4 (3.7) −7.4 (6.5)
Negative subscale 22.8 (4.3) −4.9 (5.3)
CGI-S score 4.7 (0.6) −1.1 (1.1)
NSA-16 total score 52.7 (11.8) −8.2 (11.3)
PSP score 48.2 (10.2) 11.1 (14.6)
CGI-I score at the end of treatment, mean (SD) 2.8 (1.2)
CGI-I, Clinical Global Impressions-Improvement; CGI-S, Clinical Global Impressions-Severity; N
drome Scale; PSP, Personal and Social Performance Scale.changes from baseline in lipid parameters at the end of the open-label
and double-blind treatment were generally not clinically relevant.
There were no clinically relevant mean changes in blood pressure and
no patient had QTcF or QTcB N 500 ms during the study. The incidence
of orthostatic hypotension (decrease ≥20mmHg in systolic blood pres-
sure or decrease ≥10 mm Hg in diastolic blood pressure after changing
from a supine to standing position) was lower in open-label (12.2%)
than in double-blind treatment (placebo = 18.2%; cariprazine =
20.2%). Weight gain ≥ 7% was reported in 10.6% of open-label patients,
and in 32.3% of placebo-treated patients and 27.0% of cariprazine-treat-
ed patients during double-blind treatment. Overall, ophthalmologic
testing revealed no evidence of clinically signiﬁcant lenticular changes.
Cataract TEAEs were reported in 1 patient during open-label treatment,
and in 1 placebo- and 2 cariprazine-treated patients during double-
blind treatment; confounding factors were present in each case.
3.3.3. Treatment-emergent extrapyramidal symptoms
In open-label treatment, the incidence of rating scale-derived treat-
ment-emergent parkinsonism (SAS score ≤ 3 at baseline and N3 at any
postbaseline assessment) and akathisia (BARS score ≤ 2 at baseline
and N2 at any postbaseline assessment) was 16.1% and 21.0%, respec-
tively. During double-blind treatment, more placebo-treated than
cariprazine-treated patients reported treatment-emergent parkinson-
ism (8.1% vs 5.0%) and akathisia (10.1% vs 8.0%). Among cariprazine-
and placebo-treated patients, antiparkinson drugs (for EPS) were used
by 19.8% and 19.2%, and propranolol (for akathisia) was used by 10.9%
and 8.1%.
3.3.4. Rescue medication
Overall, 193 (25.2%) patients received lorazepam as rescue medica-
tion for agitation, irritability, hostility, and restlessness during open-
label treatment, with use decreasing over time (i.e., 22% during the
ﬁrst 2 weeks and 1% by week 6). During double-blind treatment, 8
(8.1%) placebo- and 6 (5.9%) cariprazine-treated patients received res-
cuemedication (lorazepamor oxazepam, in countrieswhere lorazepam
is not readily available).
3.3.5. Suicidal ideation and behavior
According to Columbia-Suicide Severity Rating Scale (C-SSRS)
(Posner et al., 2011) ﬁndings, suicidal ideation was reported in 29
(3.9%) patients during open-label treatment, and in 2 (2.0%) placebo-
and 1 (1.0%) cariprazine-treated patients during double-blind treat-
ment; most reports were in the least serious categories (wish to be
dead; nonspeciﬁc suicidal thoughts). Suicidal ideation AEs were report-
ed in 11 patients (1.4%) during open-label treatment (5 events were
considered SAEs); no suicidal ideation TEAEswere reported during dou-
ble-blind treatment. The only report of suicidal behavior occurred dur-
ing open-label treatment in a patient with a history of suicidalDouble-blind phase
Placebo
n= 99
Cariprazine 3–9 mg/d
n= 101
Baseline (SD) Mean change (SD) Baseline (SD) Mean change (SD)
50.5 (6.1) 13.2 (18.8) 51.3 (7.2) 5.0 (14.2)
11.5 (2.4) 4.3 (6.3) 11.8 (2.9) 1.3 (5.5)
14.3 (3.1) 2.4 (4.3) 14.2 (3.4) 1.4 (3.5)
2.6 (0.6) 0.7 (1.3) 2.8 (0.6) 0.1 (0.9)
38.2 (9.4) 4.1 (11.0) 39.1 (10.2) 0.6 (8.3)
68.3 (9.2) −7.2 (16.2) 66.8 (11.4) 0.0 (9.1)
3.1 (1.7) 2.5 (1.4)
SA-16, 16-Item Negative Symptom Assessment Scale; PANSS, Positive and Negative Syn-
Table 4
Adverse events (open-label and double-blind safety populations).
Open-label
phase
Double-blind
phase
Cariprazine
3–9 mg/d
(n= 765)
Placebo
(n= 99)
Cariprazine
3–9 mg/d
(n= 101)
Summary of events, n (%)
Deaths 0 0 0
Treatment-emergent AEs 612 (80.0) 64 (64.6) 75 (74.3)
AEs leading to discontinuation 99 (12.9) 15 (15.2) 14 (13.9)
Serious AEs 50 (6.5) 14 (14.1) 14 (13.9)
Newly emergent AEs NA 64 (64.6) 71 (70.3)
Common treatment-emergent adverse events, n (%)a
Akathisia 147 (19.2) 3 (3.0) 5 (5.0)
Insomnia 110 (14.4) 8 (8.1) 8 (7.9)
Headache 92 (12.0) 7 (7.1) 7 (6.9)
Restlessness 71 (9.3) 2 (2.0) 2 (2.0)
Extrapyramidal disorder 56 (7.3) 3 (3.0) 6 (5.9)
Nausea 48 (6.3) 2 (2.0) 3 (3.0)
Dyspepsia 44 (5.8) 0 0
Weight increased 44 (5.8) 3 (3.0) 4 (4.0)
Constipation 39 (5.1) 3 (3.0) 4 (4.0)
Anxiety 38 (5.0) 3 (3.0) 4 (4.0)
Tremor 38 (5.0) 0 8 (7.9)
Diarrhea 29 (3.8) 5 (5.1) 4 (4.0)
Schizophrenia 26 (3.4) 13 (13.1) 8 (7.9)
Nasopharyngitis 13 (1.7) 5 (5.1) 8 (7.9)
Blood creatine phosphokinase increased 21 (2.7) 3 (3.0) 5 (5.0)
Back pain 17 (2.2) 2 (2.0) 5 (5.0)
A newly emergent AE was an AE that was not present before the ﬁrst dose of double-blind treatment or that increased in severity during the double-blind phase.
AE, adverse event; NA, not applicable.
a Reported in ≥5% of patients in the open-label safety population or either treatment group in the double-blind safety population.
269S. Durgam et al. / Schizophrenia Research 176 (2016) 264–271ideation/prior suicide attempt; the event was an SAE (suicide attempt)
and the patient was discontinued from the study.
4. Discussion
This relapse prevention study examined patientswith schizophrenia
who completed 20 weeks of open-label cariprazine before randomiza-
tion to continued treatment with cariprazine or placebo for up to
72weeks of double-blind treatment. Patients randomized to cariprazine
versus placebo had a signiﬁcantly longer time to relapse and signiﬁcant-
ly lower rates of relapse (24.8% vs 47.5%). The hazard of relapse for
cariprazine-treated patients was less than half that for placebo-treated
patients. Mean scores on additional efﬁcacy measures improved during
open-label cariprazine treatment, and a clearer trend of symptomwors-
ening was seen in patients randomized to placebo compared with
cariprazine during double-blind treatment.
To provide context for these results, estimated relapse rates in a
meta-analysis evaluating 1-year relapse in schizophrenia were 27%
and 64% for antipsychotic drugs and placebo, respectively (Leucht et
al., 2012); the analyses included both oral and depot agents, and
depot preparations reduced relapse more than did oral drugs. Although
comparing relapse rates among antipsychotic agents is difﬁcult due to a
lack of consensus about what constitutes relapse in schizophrenia
(Kane, 2007), the time to relapse for placebo-treated patients in our
study appears to be longer than in other relapse studies. For example,
in several schizophrenia relapse prevention trials, patients switching
from antipsychotic to placebo had relapse rates of ~15%–30% during
the ﬁrst 4 weeks of double-blind treatment, with separation between
treatment groups typically occurring within 2–3 weeks of randomiza-
tion (Arato et al., 2002; Beasley et al., 2003; Kane et al., 2011; Pigott et
al., 2003). Conversely, only 3% of placebo patients relapsed during the
ﬁrst 4 weeks of double-blind treatment in our study, suggesting that
some residual treatment effect may have persisted after cariprazine
was discontinued. Between-group separation of the curves did not
occur until around day 50 and the 25th percentile for time to relapsewas 92 days in the placebo group. Low rates of relapse in the ﬁrst
month after discontinuation of cariprazine may be related to its longer
half-life relative to other antipsychotics, which almost all have a plasma
half-life of 1 to 2 days (Taylor, 2009). In contrast, while the calculated ef-
fective half-life for cariprazine and desmethyl-cariprazine was approxi-
mately 2 days, it was considerably longer for the didesmethyl-
cariprazine metabolite (8.4 days) and the total active moieties
(1 week) (Nakamura et al., 2016).
Although relapse can be decreased by uninterrupted pharmacother-
apy (Kane, 2007), the majority of patients with schizophrenia are at
least partially nonadherent to medication (Leucht and Heres, 2006).
Since tolerability issues contribute to medication nonadherence
(Leucht and Heres, 2006), it is important to note that cariprazine was
generally well tolerated in this long-term study, with the vast majority
of AEs consideredmild tomoderate in severity. SAEs and AEs that led to
discontinuationweremost commonly associatedwithworsening of the
underlying psychiatric condition. Akathisia, themost commonly report-
ed TEAE in open-label treatment, was mild or moderate in the vast ma-
jority of patients during the study; it accounted for discontinuation of
only 1% of patients in open-label treatment and no patients in double-
blind treatment.
Limitations of the study include the lack of an active comparator and
the lownumber of open-label completers. The low completion rate dur-
ing the open-label phasewas largely due to the high rates ofwithdrawal
of consent and the requirement that patients meet stringent efﬁcacy
criteria to progress through open-label treatment. Withdrawal of con-
sent was the most common reason for early discontinuation, and fol-
low-up revealed that many of these patients were unable or unwilling
to participate in a trial of this long duration (up to 92 weeks). Addition-
ally, AEs were another common reason for discontinuation; it is worth
noting, however, that the most common cause of AE discontinuation
was worsening of the underlying psychiatric condition. Insufﬁcient
therapeutic response (e.g., lack of improvement) is also categorized as
a reason for discontinuation, although it is not considered an AE. In
this vein, worsening of schizophrenia can reasonably be considered as
270 S. Durgam et al. / Schizophrenia Research 176 (2016) 264–271an event that reﬂects a lack of response as opposed to a lack of tolerabil-
ity. Although high open-label dropout was generally not due to tolera-
bility issues, it may affect the ability to generalize these results. As is
common in relapse prevention studies, the double-blind population
had already been stabilized on cariprazine; as such, patients with unac-
ceptable AEs or tolerability problems during open-label treatmentwere
not part of the double-blind analyses and the double-blind AE proﬁle
should be interpreted with caution.
5. Conclusion
In this relapse prevention study in patients with schizophrenia, the
time to relapsewas signiﬁcantly longer and rates of relapse were signif-
icantly lower for cariprazine versus placebo. The hazard of relapse for
cariprazine-treated patients was calculated to be less than half that for
placebo-treated patients.Mean scores on additional efﬁcacy parameters
suggested symptom improvement for patients taking open-label
cariprazine, and less worsening of symptoms for double-blind
cariprazine-treated patients than for placebo-treated patients. The
long-term safety proﬁle was consistent with that observed in previous
cariprazine clinical trials. Results from this trial suggest that cariprazine
may be useful in delaying or preventing relapse in schizophrenia.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2016.06.030.
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